Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Trastuzumab infusion	TA257 - Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 TA34 - Guidance on the use of trastuzumab for the treatment of advanced breast cancer TA208 - Trastuzumab for the treatment of HER2-positive metastatic gastric cancer TA107 - Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer	Funding approval should be sought prior to initiation
Trimovate cream	TA81 - Frequency of application of topical corticosteroids for atopic eczema	Moderate potency.
Upadacitinib (Rinvoq®)	TA665 - Upadacitinib for treating severe rheumatoid arthritis TA744 - Upadacitinib for treating moderate rheumatoid arthritis TA829 - Upadacitinib for treating active ankylosing spondylitis TA861 - Upadacitinib for treating active non-radiographic axial spondyloarthritis
Upadacitinib (Rinvoq®)	TA856 - Upadacitinib for treating moderately to severely active ulcerative colitis TA907 - Deucravacitinib for treating moderate to severe plaque psoriasis
Ustekinumab	TA180 - Ustekinumab for the treatment of adults with moderate to severe psoriasis	Hospital use only
Ustekinumab (Stelara®)	TA456 - Ustekinumab for moderately to severely active Crohn’s disease after previous treatment TA456 - Ustekinumab for treating moderately to severely active ulcerative colitis
Ustekinumab	TA180 - Ustekinumab for the treatment of adults with moderate to severe psoriasis
Varenicline (Champix®)	TA123 - Varenicline for smoking cessation
Vedolizumab	TA342 - Vedolizumab for treating moderately to severely active ulcerative colitis TA352 - Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy	Hospital only - use in line with NICE Off label use - for the treatment of refractory immunotherapy-related colitis
Vemurafenib tablets	TA269 - Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma	National CDF list

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.